On July 8, 2016 Alligator Bioscience AB is a privately held Swedish biotech company developing immuno-oncology antibodies for tumor-directed immunotherapy (Press release, Alligator Bioscience, JUL 8, 2016, View Source [SID1234538692]). Alligator reported has contracted BioInvent for process development and cGMP manufacturing of the immuno-oncology drug candidate ADC-1015. The agreement will supply Alligator with ADC-1015 Drug Product for early clinical trials.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Alligator has a strong pipeline consisting of 5 drug candidates. ADC-1013 is an immune activating antibody directed against CD40, developed for treatment of metastatic cancer. Clinical trials in cancer patients were initiated early 2015, and ADC-1013 was later the same year out-licensed to Janssen Biotech, a Johnson & Johnson oncology company. ADC-1015 is a bispecific immune activating antibody that targets OX40 and CTLA-4. Since both OX40 and CTLA-4 are expressed on T cells in the tumor area, ADC-1015 is expected to induce strong tumor-directed immune activation. ADC-1015 has the potential to become first-in-class in this category of immune activating bispecific antibodies. In addition to ADC-1013 and ADC-1015, Alligator has three drug candidates in research phase.

For further information, please contact:

Per Norlén, CEO Alligator Bioscience AB, Office number: +46 46 2864280